Executive Summary: 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis

• Main Authors: Galgiani, John N., Ampel, Neil M., Blair, Janis E., Catanzaro, Antonino, Geertsma, Francesca, Hoover, Susan E., Johnson, Royce H., Kusne, Shimon, Lisse, Jeffrey, MacDonald, Joel D., Meyerson, Shari L., Raksin, Patricia B., Siever, John, Stevens, David A., Sunenshine, Rebecca, Theodore, Nicholas
• Other Authors: Univ Arizona, Valley Fever Ctr Excellence
• Language: en
• Published: OXFORD UNIV PRESS INC 2016
• Subjects: coccidioidomycosis; antifungal treatment; community acquired pneumonia; travel history; immunocompromised patients
• Online Access: http://hdl.handle.net/10150/622157; http://arizona.openrepository.com/arizona/handle/10150/622157

It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. Infectious Diseases Society of America considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances. Coccidioidomycosis, also known as San Joaquin Valley fever, is a systemic infection endemic to parts of the southwestern United States and elsewhere in the Western Hemisphere. Residence in and recent travel to these areas are critical elements for the accurate recognition of patients who develop this infection. In this practice guideline, we have organized our recommendations to address actionable questions concerning the entire spectrum of clinical syndromes. These can range from initial pulmonary infection, which eventually resolves whether or not antifungal therapy is administered, to a variety of pulmonary and extrapulmonary complications. Additional recommendations address management of coccidioidomycosis occurring for special at-risk populations. Finally, preemptive management strategies are outlined in certain at-risk populations and after unintentional laboratory exposure.